Clinical ink, a provider in eSource solutions, as appointed Andrew Kraus as chief technology officer to lead the development of its expanding technology portfolio to support clinical trials. 
 
“I am passionate about making a meaningful difference for patient by streamlining the clinical trials process,” said Kraus. “There is so much opportunity to simplify the capture of clinical data from patient. I’m excited to drive innovation as part of the Clinical ink team as we lead the industry in the development and deployment of integrated clinical trial technologies.”
 
For 30 years Kraus has been an innovator in clinical trials through his background in technology, operations, strategy, and finance. He currently sits on the board of directors for specialized clinical data services company Algorics. 
 
Prior to Clinical ink, Kraus was COO at World Care Clinical, a CRO providing centralized imaging and other services supporting clinical trials. Kraus also held previous roles at Bioclinica (now part of Clario), Signant, and the Cardiovascular Research Foundation.
 
Having co-founded Beacon Bioscience, Kraus has a deep understanding of the clinical trial space and oversaw its growth into a global imaging and clinical event adjunction provider as chief technology officer at Beacon Bioscience. The company was acquired by ICON plc, becoming ICON Medical Imaging where Kraus managed all imaging and data technology business. 
 
“I am delighted that Andrew has joined up at CTO, said Clinical ink CEO Jonathan Goldman. “He brings tremendous expertise in the use of technology to solve unmet needs in clinical trials and patient care to our organization. He is the right person to lead the growth of our patient-centered technology platform.”